A Global Effort Anchored in Singapore
The fight against triple-negative breast cancer (TNBC) has long been defined by its aggressive nature and limited treatment options. For the roughly 70% of patients with advanced TNBC who are ineligible for immunotherapy, first-line chemotherapy has remained the default—a strategy with modest efficacy and a median progression-free survival of just 5.6 months. That reality is now being rewritten, thanks to a global phase III clinical trial led by a senior medical oncologist at the National Cancer Centre Singapore (NCCS).
The TROPION-Breast02 trial, published in Annals of Oncology on 3 April 2026, evaluated the novel antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) in 644 patients with untreated, advanced TNBC across multiple sites including Singapore, the United States, Canada, Europe, China, Korea, and Japan. The results were striking: median progression-free survival nearly doubled to 10.8 months for patients receiving Dato-DXd, compared to 5.6 months for those on chemotherapy. Overall survival also improved significantly, with a median of 23.7 months versus 18.7 months.
How Dato-DXd Works and Why It Matters
Dato-DXd is an ADC that targets the TROP2 protein, which is highly expressed in TNBC cells. By delivering a potent cancer-killing drug directly to tumour cells, the therapy minimises damage to healthy tissue while maximising anti-tumour activity. The trial’s overall response rate was 63% for the Dato-DXd arm, more than double the 29% observed in the chemotherapy arm. Median duration of response was also superior: 12.3 months versus 7.1 months.
For Professor Rebecca Dent, Deputy CEO (Clinical) and Senior Consultant at NCCS, who led the trial, the findings represent a career-defining moment. “As a medical oncologist treating triple-negative breast cancer patients for the past 20 years, I am deeply encouraged that this data shows we now have a much-needed new tool to help women affected by this devastating disease,” she said.
The Real-World Impact
TNBC disproportionately affects young women under 40 and is associated with early recurrence and high metastatic potential. Approximately half of patients with metastatic TNBC do not receive treatment beyond first-line chemotherapy, underscoring the urgent need for effective alternatives. The TROPION-Breast02 results offer a viable second-line option that could fundamentally alter clinical practice. The trial’s findings have already been submitted for regulatory review, with the potential to expand Dato-DXd’s approved indications beyond its current use in hormone receptor-positive, HER2-negative breast cancer.
